This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 211.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Annovis Bio (ANVS) stock based on the movements in the options market lately.
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
by Zacks Equity Research
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
by Ekta Bagri
Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.
CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer
by Zacks Equity Research
If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.
Annovis (ANVS) AD Study to Continue as Planned, Shares Rise
by Zacks Equity Research
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any additional patients.
Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study
by Zacks Equity Research
Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
by Zacks Equity Research
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.
Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update
by Zacks Equity Research
Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.
Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro
by Zacks Equity Research
Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.
Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody
by Zacks Equity Research
Coherus (CHRS) resubmits biologics license application for Udenyca Onbody, an on-body injector presentation of Udenyca to the FDA. Stock rises.
Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion
by Zacks Equity Research
Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.
Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.
Apellis (APLS) Provides Syfovre Q3 Preliminary Revenues Guidance
by Zacks Equity Research
Apellis' (APLS) shares rise as it provides third-quarter 2023 preliminary revenues guidance for Syfovre, approved for the treatment of geographic atrophy.
Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin
by Zacks Equity Research
Orchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American Depositary Share, which amounts to a total transaction value of approximately $478 million. Shares rise 97%.
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
by Zacks Equity Research
Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.
Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce
by Zacks Equity Research
Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.
Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies
by Zacks Equity Research
Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.
Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine
by Zacks Equity Research
Per the terms of the deal, Sanofi (SNY) and J&J will co-fund current and future R&D costs to develop a potential first-in-class vaccine against extraintestinal pathogenic E. coli.
Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH
by Zacks Equity Research
Apellis (APLS) receives the FDA approval for Empaveli Injector, a self-administred on-body device, to treat patients with paroxysmal nocturnal hemoglobinuria.
NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up
by Zacks Equity Research
NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.
Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug
by Zacks Equity Research
If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studies support the FDA filing.
Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug
by Zacks Equity Research
Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.
Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
by Zacks Equity Research
Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.
Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug
by Zacks Equity Research
Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.